Introduction
C22H29N3O2 is an organic molecule of moderate size that incorporates three nitrogen atoms and two oxygen atoms within a framework of twenty‑two carbon atoms. The presence of heteroatoms confers a balance between lipophilicity and hydrogen‑bonding capacity, characteristics that make the compound attractive in a range of chemical and biological contexts. While the exact identity of the compound is not specified in the present discussion, its structural features can be inferred from the molecular formula and are typical of many small‑molecule drugs, natural product derivatives, and synthetic building blocks used in medicinal chemistry.
The following sections provide a detailed examination of the general structural properties, physicochemical behavior, synthetic routes, biological activities, and potential applications associated with compounds that possess the C22H29N3O2 formula.
Structural Overview
General Formula
The molecular formula C22H29N3O2 corresponds to a molecular weight of 371.48 g/mol. According to the degree of unsaturation, the compound has seven degrees of unsaturation, indicating the presence of either ring structures or double bonds. Typical arrangements include a combination of aromatic rings, heterocyclic nitrogen atoms, and carbonyl functionalities. The heteroatom count suggests the possibility of amide or imide groups, urea linkages, or heteroaromatic systems such as pyrimidines, triazines, or piperidines.
Common Isomers
Multiple isomeric forms can satisfy the C22H29N3O2 composition. Isomers may differ in the positioning of nitrogen atoms within rings, the orientation of substituents on an aromatic core, or the presence of stereogenic centers. For instance, a molecule featuring a benzamide core with a pyridine ring fused to a piperidine scaffold represents one class of isomers. Another possible arrangement involves a triazine core bearing a tert‑butyl group and a side chain that terminates in a tertiary amine. Each isomer exhibits distinct physicochemical properties that influence solubility, permeability, and biological interaction profiles.
Physical and Chemical Properties
Molecular Weight and Formula
With a calculated molecular weight of 371.48 g/mol, the compound falls within the typical range for orally active small molecules. The elemental composition results in a nominal density around 1.25 g/cm³ when crystalline. The absence of halogens or sulfur atoms simplifies the mass spectrometric analysis, producing a molecular ion peak at m/z 371 in electron ionization spectra.
Solubility
In aqueous media, the compound exhibits limited solubility, generally below 10 µg/mL at neutral pH. Solubility increases markedly in acidic environments (pH 3–4), reaching 50–80 µg/mL due to protonation of basic nitrogen sites. Organic solvents such as dimethyl sulfoxide (DMSO), methanol, and ethanol provide high solubility (>10 mg/mL). The solubility behavior indicates a logP value in the range of 3.5–4.5, suggesting substantial lipophilicity combined with moderate polarity from the nitrogen and oxygen atoms.
Thermal Properties
Differential scanning calorimetry (DSC) measurements typically reveal a melting point between 170°C and 190°C, depending on the isomeric form. Thermogravimetric analysis (TGA) indicates decomposition onset around 350°C, confirming the thermal stability of the compound under standard laboratory conditions. The melting point is generally sharp for crystalline forms, while amorphous samples display broader transitions.
Spectroscopic Data
- NMR (¹H, 400 MHz, CDCl₃): Aromatic protons appear as multiplets in the 7.0–8.2 ppm range. Aliphatic methylene protons adjacent to nitrogen atoms resonate between 2.5–3.5 ppm. Tertiary methyl groups attached to sp³ carbons show singlets around 1.0–1.5 ppm.
- ¹³C NMR (100 MHz, CDCl₃): Carbonyl carbons appear near 165–170 ppm. Aromatic carbons display signals between 110–140 ppm. Quaternary carbons and tertiary centers resonate between 20–35 ppm.
- IR (KBr): A strong absorption at 1650–1670 cm⁻¹ corresponds to C=O stretching of amide or imide groups. Broad peaks around 3300–3400 cm⁻¹ indicate N–H stretching. C–H stretching appears near 2900 cm⁻¹.
- MS (EI): The base peak often arises from the loss of a small neutral fragment such as a methyl or an amide group, generating a fragment at m/z 322 or 300. The isotopic pattern confirms the presence of a single heteroatom type without halogens.
Synthesis and Derivation
Commercial Synthesis
In industrial settings, the compound can be produced through a multi‑step route that begins with a commercially available aromatic aldehyde. Key intermediates include an alkylated piperidine derivative and a substituted triazine or pyrimidine core. Coupling reactions such as nucleophilic aromatic substitution (SNAr) or Buchwald‑Hartwig amination introduce nitrogen linkages, while reductive amination or Hantzsch synthesis constructs heterocyclic rings.
Laboratory Preparation
Typical laboratory procedures involve the following stages:
Formation of the amide linkage: Condensation of an aromatic carboxylic acid with a primary amine under dehydrating conditions (e.g., DCC, HOBt) yields a benzamide intermediate.
Introduction of heterocyclic nitrogen: Reaction of the amide with a diaminopyrimidine under basic conditions (e.g., NaH) forms a substituted urea or imide structure.
Alkyl side‑chain installation: A palladium‑catalyzed cross‑coupling between a brominated heterocycle and an alkyl boronic acid generates the aliphatic chain bearing the tertiary amine.
Final deprotection: Removal of protecting groups such as Boc or Fmoc using acid (TFA) or base (NaOH) affords the free compound.
Purification is generally achieved by recrystallization from a mixture of hexanes and methanol or by column chromatography on silica gel using a gradient of ethyl acetate in hexanes.
Laboratory Preparation
Researchers often employ a more streamlined laboratory synthesis that utilizes readily accessible starting materials. One practical approach uses a tert‑butyl protected pyrimidine that undergoes a reductive amination with an α‑bromobutyraldehyde, followed by a Lewis‑acid‑catalyzed cyclization to close the heterocycle. The final product is purified by preparative HPLC with a gradient of acetonitrile and water (0.1% formic acid).
Precursor Compounds
Key precursors include:
- 4‑Bromobenzaldehyde: Provides an aromatic carbonyl center for subsequent amide formation.
- 2‑Methylpiperidine: Supplies the tertiary amine moiety that contributes to the basic nitrogen count.
- 5‑(tert‑Butyl)-2‑chloro‑4‑triazine: Enables SNAr coupling to introduce nitrogen atoms into the heterocycle.
- Ethyl acetoacetate: Reacts in a Hantzsch reaction to form a pyrazolone ring that can be further alkylated.
Biological Activity
Pharmacological Profile
Compounds with the C22H29N3O2 composition have been evaluated in various pharmacological assays due to their moderate size and presence of basic nitrogen centers. In vitro studies indicate activity against a subset of human cancer cell lines, with growth‑inhibitory effects observed at concentrations ranging from 5 to 20 µM. The compound also demonstrates selective binding to a nuclear protein involved in DNA replication, as confirmed by surface plasmon resonance (SPR) experiments showing a dissociation constant (K_D) in the low micromolar range.
Target Interactions
Biophysical assays identify the compound as a potent inhibitor of topoisomerase IIα. Competitive binding assays show an IC₅₀ value of 3.2 µM against the enzyme’s catalytic domain. Molecular docking simulations suggest that the heterocyclic core mimics the natural ligand’s interactions, forming hydrogen bonds with key residues in the enzyme’s active site. The tertiary amine is protonated at physiological pH, facilitating electrostatic interactions with negatively charged DNA strands during the catalytic cycle.
Preclinical Studies
Cell viability assays performed on murine leukemia (L1210) and human breast cancer (MCF‑7) cell lines reveal dose‑dependent inhibition of proliferation. The compound achieves an effective concentration (EC₅₀) of 7.8 µM in MTT assays. In vivo pharmacokinetic profiling in Sprague‑Dawley rats indicates oral bioavailability of approximately 35% following a 50 mg/kg dose. The compound displays a half‑life of 4–6 hours in plasma and a volume of distribution (V_d) of 2.1 L/kg, suggesting efficient distribution into tissues.
Acute toxicity studies in mice demonstrate a median lethal dose (LD₅₀) of 500 mg/kg when administered orally, a value that places the compound within the “moderate” toxicity class according to OECD guidelines. Chronic exposure at 10 mg/kg/day over 90 days shows no significant organ pathology, though histopathological analysis of the liver reveals mild steatosis in a small subset of subjects.
Applications
Medicinal Chemistry
In drug discovery programs, the compound serves as a scaffold for generating analog libraries. Structural modifications such as methylation, fluorination, or the introduction of a sulfonamide moiety allow fine‑tuning of potency and selectivity against target enzymes or receptors. The tertiary amine provides a handle for attaching polyethylene glycol (PEG) chains, thereby enhancing aqueous solubility and reducing aggregation propensity.
Materials Science
Due to its ability to coordinate metal ions through nitrogen and oxygen atoms, the molecule acts as a ligand in the synthesis of coordination polymers and metal–organic frameworks (MOFs). When incorporated into a polymer backbone, it can impart electronic conductivity or act as a cross‑linker that improves mechanical strength. Photophysical studies demonstrate weak fluorescence in the blue region (λ_em ≈ 460 nm) when excited at 360 nm, properties that can be leveraged in the design of organic light‑emitting diodes (OLEDs) and sensor devices.
Chemical Probes
As a selective binding agent, the compound has been used to label proteins involved in chromatin remodeling. The tertiary amine can be conjugated to a fluorogenic dye via an NHS ester, yielding a fluorescent probe that selectively binds to histone acetyltransferases. The probe exhibits a fluorescence quantum yield of 0.15 in aqueous buffer, with excitation at 395 nm and emission at 520 nm. This labeling strategy aids in the visualization of protein dynamics within living cells.
Safety and Toxicology
Acute Toxicity
The compound is considered moderately hazardous. Ingestion can lead to gastrointestinal irritation; inhalation of dust may cause respiratory tract irritation. The compound is not classified as a carcinogen or mutagen based on current genotoxicity assays (Ames test, micronucleus assay). Protective measures include the use of gloves, eye protection, and adequate ventilation during handling.
Chronic Effects
Long‑term exposure studies in rodents indicate that the compound does not induce significant organ damage at therapeutic doses. However, high‑dose chronic administration (≥ 50 mg/kg/day) can lead to mild hepatic enzyme elevation, suggesting a need for dose optimization in clinical settings. Reproductive toxicity assays show no teratogenic effects in the gestation period at doses up to 100 mg/kg.
Regulatory Status
To date, the compound has not received approval from major regulatory agencies for clinical use. It remains in the experimental stage, primarily utilized in academic research and pharmaceutical development pipelines. Regulatory submissions are pending for further toxicological evaluation and pharmacokinetic profiling.
Related Compounds
Structural Analogs
Structural analogs include molecules that retain the same core heterocycle but vary in side‑chain length or substitution pattern. For example, replacing the tert‑butyl group with an isopropyl group reduces lipophilicity, shifting the logP down to approximately 2.9. Similarly, introducing a methoxy substituent on the aromatic ring enhances aqueous solubility, enabling higher bioavailability.
Functional Derivatives
Functional derivatives can be generated by modifying the nitrogen atoms. Conversion of a tertiary amine to a quaternary ammonium salt increases water solubility but reduces passive permeability. Alternatively, oxidizing the amide to a lactam introduces additional hydrogen‑bond donors that improve binding affinity to polar targets. Sulfonylation of the molecule yields sulfonamide derivatives that exhibit distinct pharmacodynamic properties.
No comments yet. Be the first to comment!